Form 4: Day One Biopharmaceuticals Director Habib Dable Granted New Stock Options and Restricted Stock Units

Day One Biopharmaceuticals, Inc. Director Habib J. Dable was granted 22,500 stock options and 15,000 restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

Summary

• Habib J. Dable, a Director of Day One Biopharmaceuticals, Inc. (DAWN), reported new equity grants in a Form 4 filing dated June 4, 2025.
• On June 2, 2025, Mr. Dable was granted 22,500 stock options to purchase Common Stock.
• These stock options have an exercise price of $7.01 per share.
• The options will vest as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to his continued provision of service to the Issuer.
• The expiration date for these stock options is June 1, 2035.
• Additionally, on June 2, 2025, Mr. Dable received 15,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• The RSUs will vest 100% on the earlier of June 2, 2026, and the date of the Issuer's 2026 annual meeting of stockholders, subject to his continued service.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is a positive for aligning interests, but does not contain information that would significantly alter the company's fundamental outlook or financial performance in the short term. It's a neutral-to-slightly positive administrative filing.

Positives

• The grant of stock options and restricted stock units to a director aligns his interests with the long-term shareholder value creation of Day One Biopharmaceuticals.
• The structured vesting schedules for both the options and RSUs incentivize continued service and commitment from the director, promoting stability in governance.

Risks

• The ultimate value realized from the stock options and RSUs is contingent on the future performance of Day One Biopharmaceuticals' stock price.
• Vesting of both the stock options and RSUs is subject to the reporting person's continued provision of service to the Issuer; unvested portions could be forfeited if service ceases.

Future Outlook

The grants of stock options and RSUs to Director Habib J. Dable indicate a long-term incentive structure designed to align his interests with the future performance and growth of Day One Biopharmaceuticals, Inc. The vesting schedules extend into 2026 and 2035, suggesting an expectation of continued service and contribution from the director.

Industry Context

This Form 4 filing is a standard disclosure of equity compensation for a director in the biotechnology or pharmaceutical industry. Such grants are common practice to attract and retain executive talent and align their incentives with shareholder value creation, particularly in growth-oriented sectors like biopharmaceuticals where long-term development cycles are prevalent.

Comparison to Industry Standards

• Equity grants of stock options and restricted stock units are standard compensation practices for directors in the biopharmaceutical industry.
• The specific amounts (22,500 options, 15,000 RSUs) and vesting schedules (monthly for options, cliff vesting for RSUs) are typical for incentivizing long-term commitment.
• Without specific comparable companies' director compensation data, a direct quantitative comparison is not feasible from this document alone. However, the structure of the compensation package is consistent with industry norms for aligning director interests with company performance.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value creation, as the value of his compensation is directly tied to the company's stock performance.

Next Steps

• Continued monthly vesting of stock options beginning July 2, 2025.
• Vesting of Restricted Stock Units on the earlier of June 2, 2026, or the 2026 annual meeting of stockholders.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership